<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143607</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-LC-120067-F-III</org_study_id>
    <nct_id>NCT04143607</nct_id>
  </id_info>
  <brief_title>ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC</brief_title>
  <official_title>A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth&#xD;
      factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or&#xD;
      Metastatic Non Small Cell Lung Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Triple (Participant, Investigator, Outcomes Assessor)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years</time_frame>
    <description>Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy prior to progression and was used to assess the efficacy of single agent ASK120067 compared with Gefitinib as measured by PFS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years</time_frame>
    <description>ORR was defined as the number (%) of patients with measurable disease with at least 1 visit response of Complete response (CR) or Partial response (PR) and it was used to further assess the efficacy of ASK120067 compared with Gefitinib defined as the number (%) of patients with measurable disease with at least 1 visit response of Complete response (CR) or Partial response (PR) and it was used to further assess the efficacy of ASK120067 compared with Gefitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years</time_frame>
    <description>Duration of response was defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression and was used to further assess the efficacy of ASK120067 compared with Gefitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years</time_frame>
    <description>The DCR was defined as the percentage of participants who had a best overall response (BOR) of Complete response (CR), Partial response (PR) or Stable disease (SD) ≥6 weeks prior to any Progressive disease (PD) event and was used to further assess the efficacy of ASK120067 compared with Gefitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of Response</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years</time_frame>
    <description>The Depth of response was defined as the relative change in the sum of the longest diameters of Response Evaluation Criteria in Solid Tumors (RECIST) Target lesions (TLs) at the nadir, in the absence of new lesions (NLs) or progression of Non-target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)- Number of Participants With an Event</measure>
    <time_frame>Time from treatment start to the time of death due to any cause or withdrawal from study,whichever came first, assessed up to approximately 5 years</time_frame>
    <description>Overall survival was defined as the time from the date of randomisation until death from any cause and was used to further assess the efficacy of ASK120067 compared with Gefitinib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Locally Advanced or Metastatic NSCLC</condition>
  <arm_group>
    <arm_group_label>ASK120067+ placebo Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASK120067 (160 mg or 80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib + placebo ASK120067</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (160 mg or 80 mg orally, twice daily), in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASK120067</intervention_name>
    <description>The initial dose of ASK120067 160 mg twice daily can be reduced to 80 mg twice daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.</description>
    <arm_group_label>ASK120067+ placebo Gefitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gefitinib 250 mg</intervention_name>
    <description>The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.</description>
    <arm_group_label>ASK120067+ placebo Gefitinib</arm_group_label>
    <other_name>Placebo Iressa 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib (250 mg orally, once daily) , in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).</description>
    <arm_group_label>Gefitinib + placebo ASK120067</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ASK120067</intervention_name>
    <description>The initial dose of Placebo ASK120067 160 mg once daily can be reduced to Placebo ASK120067 80 mg twice daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.</description>
    <arm_group_label>Gefitinib + placebo ASK120067</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged at least 18 years.&#xD;
&#xD;
          2. Pathologically confirmed adenocarcinoma of the lung.&#xD;
&#xD;
          3. Locally advanced or metastatic NSCLC, not amenable to curative surgery or&#xD;
             radiotherapy.&#xD;
&#xD;
          4. The tumour harbours one of the 2 common EGFR mutations known to be associated with&#xD;
             EGFR-TKI sensitivity (Ex19del, L858R).&#xD;
&#xD;
          5. Mandatory provision of an unstained, archived tumour tissue sample in a quantity&#xD;
             sufficient to allow for central analysis of EGFR mutation status.&#xD;
&#xD;
          6. Patients must be treatment-naïve for locally advanced or metastatic NSCLC and eligible&#xD;
             to receive first-line treatment with gefitinib as selected by the participating&#xD;
             centre. Prior adjuvant and neo-adjuvant therapy is permitted(chemotherapy,&#xD;
             radiotherapy, investigational agents).&#xD;
&#xD;
          7. Provision of informed consent prior to any study specific procedures, sampling, and&#xD;
             analysis.&#xD;
&#xD;
          8. ECOG score of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any of the following:&#xD;
&#xD;
               -  Prior treatment with any systemic anti-cancer therapy for locally&#xD;
                  advanced/metastatic NSCLC.&#xD;
&#xD;
               -  Prior treatment with an EGFR-TKI.&#xD;
&#xD;
               -  Major surgery within 4 weeks of the first dose of study drug.&#xD;
&#xD;
               -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field&#xD;
                  of radiation within 4 weeks of the first dose of study drug.&#xD;
&#xD;
               -  Patients currently receiving medications or herbal supplements known to be potent&#xD;
                  inducers of cytochrome P450 (CYP) 3A4.&#xD;
&#xD;
               -  Alternative anti-cancer treatment&#xD;
&#xD;
               -  Treatment with an investigational drug within five half-lives of the compound or&#xD;
                  any of its related material.&#xD;
&#xD;
          2. Any concurrent and/or other active malignancy that has required treatment within 2&#xD;
             years of first dose of study drug.&#xD;
&#xD;
          3. Spinal cord compression, symptomatic and unstable brain metastases, except for those&#xD;
             patients who have completed definitive therapy, are not on steroids, have a stable&#xD;
             neurologic status for at least 2 weeks after completion of the definitive therapy and&#xD;
             steroids.&#xD;
&#xD;
          4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses; or active infection including hepatitis B,&#xD;
             hepatitis C and human immunodeficiency virus (HIV).&#xD;
&#xD;
          5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the formulated product, or previous significant bowel resection that would&#xD;
             preclude adequate absorption of ASK120067.&#xD;
&#xD;
          6. Any of the following cardiac criteria:Mean resting corrected QT interval (QTc) &gt;470&#xD;
             msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTcF&#xD;
             value.Any clinically important abnormalities in rhythm, conduction, or morphology of&#xD;
             resting ECG.Any patient with any factors that increase the risk of QTc prolongation or&#xD;
             risk of arrhythmic events or unexplained sudden death under 40 years of age in&#xD;
             first-degree relatives or any concomitant medication known to prolong the QT interval.&#xD;
&#xD;
          7. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required&#xD;
             steroid treatment, or any evidence of clinically active ILD.&#xD;
&#xD;
          8. Involvement in the planning and/or conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tingting Song</last_name>
    <phone>025-85100150</phone>
    <email>songtingting@ask-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Ni</last_name>
    <phone>025-85100634</phone>
    <email>niliang@ask-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi</last_name>
    </contact>
    <investigator>
      <last_name>Yuankai Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baolan Li</last_name>
    </contact>
    <investigator>
      <last_name>Baolan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Feng</last_name>
    </contact>
    <investigator>
      <last_name>Jifeng Feng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

